We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Results from two ongoing Phase III studies of Merck's Isentress (raltegravir) demonstrated significantly greater antiretroviral activity of Isentress combined with optimized background therapy (OBT) versus placebo plus OBT in treatment-experienced HIV patients.
Pharmion announced that the European Medicines Agency (EMEA) has accepted for review the company's marketing authorization application for Thalidomide Pharmion (thalidomide) for untreated multiple myeloma.
Advancis Pharmaceutical announced positive results from its meeting with the FDA regarding its once-daily Amoxicillin Pulsys product for the treatment of adolescents and adults with pharyngitis/tonsillitis (commonly referred to as strep throat).
Tibotec Pharmaceuticals presented the first results of the phase IIb dose-finding study of TMC278 at a recent conference. Based on the study findings, a 75-mg dose has been selected for Phase III development in treatment-naive patients.
A new candidate vaccine against hepatitis E, developed by GlaxoSmithKline (GSK) and the Walter Reed Army Institute of Research, was found to be 95.5 percent effective in a Phase II trial, according to a study to be published in the New England Journal of Medicine (NEJM).